HUDDINGE, Sweden, Jan. 15, 2024 /PRNewswire/ -- XNK Therapeutics AB ('XNK') today announced that evencaleucel has received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). This recommendation classifies evencaleucel as a Somatic Cell Therapy Medicinal Product (sCTMP) within the category of Advanced Therapy Medicinal Products (ATMPs).
HUDDINGE, Sweden, Dec. 4, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that Johan Liwing, CEO, will present the company at the DNB Nordic Healthcare Conference in Oslo, Norway, on December 14 at 10:15am CET.
XNK Therapeutics to present at Investival Showcase Meeting
HUDDINGE, Sweden, Sept. 27, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.
HUDDINGE, Sweden, Aug. 28, 2023 /PRNewswire/ -- The annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (?? T, ?? T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field.
HUDDINGE, Sweden, July 12, 2023 /PRNewswire/ -- XNK Therapeutics AB today announced that it has been selected as one of three winners of Business Sweden's Catalyst program 2023. The program identifies Swedish companies having the strongest prerequisites to scale up globally.
HUDDINGE, Sweden, May 24, 2023 /PRNewswire/ -- XNK Therapeutics today announced that its CEO Johan Liwing will present at ABG Sundal Collier's Life Science Summit in Stockholm, Sweden, on May 31 at 10:00am CEST.